Tirzepatide – 10mg (For Research Use Only)
Price: $200.00| HPLC-Tested · Bulk Pricing Available · Free Shipping Over $100
Description
Tirzepatide is a synthetic peptide studied for its role as a dual receptor agonist</strong) targeting both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Research has focused on its ability to modulate endocrine signaling pathways, metabolic regulation, and receptor cascade activity in controlled laboratory environments.
In preclinical studies, Tirzepatide has demonstrated selective binding to GLP-1R and GIPR, making it valuable for investigations into gastrointestinal peptide interactions, glucose-related hormonal feedback, and dual agonist activity across peptide receptor systems.
Product Specifications
- Peptide: Tirzepatide
- Concentration: 10mg per vial
- Form: Lyophilized powder
- Purity: ≥98% (HPLC Verified)
- CAS Number: 2023788-19-2
- Molecular Formula: C225H348N48O68
- Molecular Weight: ~4813.45 g/mol
- Shelf Life: 36 months when stored properly
Storage & Handling Instructions
- Reconstitute using bacteriostatic (BAC) water
- Do not shake before or after reconstitution
- Store lyophilized peptide at -20°C or colder
- Refrigerate reconstituted solution at 2–8°C
- Protect from light and moisture
Research Applications May Include:
- Dual GLP-1 and GIP receptor agonism studies
- Endocrine feedback loop modulation models
- Peptide-receptor binding affinity research
- Signal transduction cascade mapping
- Preclinical metabolic regulation pathways
Product Quality Guarantee
All Battle Born Peptides are third-party HPLC-tested. COAs are published for each batch. If tested by a certified lab and found below 98% purity, we will:
- Refund the full purchase amount
- Reimburse your third-party HPLC testing
- Cover original shipping costs
Important Notice
This product is intended strictly for laboratory research use only. It is not for human or veterinary consumption, therapeutic application, or personal use.
Reviews
There are no reviews yet